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Background: Secreted protein acidic and rich in cysteine (SPARC), a calcium-binding matricellular glycoprotein, is
implicated in the progressions of some cancers. However, no information has been available to date regarding the
function of SPARC in cervical cancer cell growth and metastasis.
Methods: In this study, we isolated and established high invasive subclones and low invasive subclones from
human cervical cancer cell lines HeLa and SiHa by the limited dilution method. Real-time q-RT-PCR, Western Blot
and ICC were performed to investigate SPARC mRNA and protein expressions in high invasive subclones and low
invasive subclones. Then lentivirus vector with SPARC shRNA was constructed and infected the highly invasive
subclones. Real-time q-RT-PCR, Western Blot and ICC were also performed to investigate the changes of SPARC
expression after viral infection. In functional assays, effects of SPARC knockdown on the biological behaviors of
cervical cancer cells were investigated. The mechanisms of SPARC in cervical cancer proliferation, apoptosis and
invasion were also researched.
Results: SPARC was over-expressed in the highly invasive subclones compared with the low invasive subclones.
Knockdown of SPARC significantly suppressed cervical cancer cell proliferation, and induced cell cycle arrest at the
G1/G0 phase through the p53/p21 pathway, also caused cell apoptosis accompanied by the decreased ratio of
Bcl-2/Bax, and inhibited cell invasion and metastasis accompanied by down-regulated MMP2 and MMP9
expressions and up-regulated E-cadherin expression.
Conclusion: SPARC is related to the invasive phenotype of cervical cancer cells. Knockdown of SPARC significantly
suppresses cervical cancer cell proliferation, induces cell apoptosis and inhibits cell invasion and metastasis. SPARC
as a promoter improves cervical cancer cell growth and metastasis.
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Cervical cancer is the second most common malignancy
in women worldwide, and it remains a leading cause of
cancer-related death for women in developing countries
[1]. About 30% of patients with International Federation
of Gynecology and Obstetrics (FIGO) stage IB2 to stage
IV will ultimately recur and metastasis [2]. Therefore,
studying the mechanisms of tumor invasion and metas-
tasis will provide further insights into the occurrence* Correspondence: zhangjie19630711@163.com; yrzhao@sdu.edu.cn
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reproduction in any medium, provided the orand development of cervical cancer. In recent years,
many genes, such as the high mobility group box l [3],
metastasis-associated 1 [4], Twist [5], and so on, have
been found correlated with the progression of cervical
cancer. However, few studies have been done to assess
the functions of SPARC in cervical cancer cell growth
and metastasis.
SPARC, also termed osteonectin, BM-40, and 43K pro-
tein, was initially identified by Termine et al. [6] as a
bone-specific phosphoprotein that binds to collagen
fibrils and hydroxyapatite at distinct sites. SPARC has
generated considerable interests as a multi-faceted pro-
tein that belongs to a family of matricellular proteins,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and cell function [7]. Recently, SPARC has been found
over-expressed in a variety of cancers and considered a
potential target for cancer therapy [8,9], but the function
of SPARC in cervical cancer cell growth and metastasis
is not fully understood.
In the present study, we isolated and established high in-
vasive subclones and low invasive subclones from human
cervical cancer cell lines HeLa and SiHa by the limited dilu-
tion method. We found that the expressions of SPARC in
high invasive subclones were much higher than that in low
invasive subclones. In the function assays, we decreased the
expressions of SPARC in high invasive subclones by
lentivirus-mediated RNA interference to determine the
effects of SPARC on cervical cancer cell proliferation, apop-
tosis, invasion and metastasis. To our knowledge, it is the
first time to clarify the function and mechanism of SPARC
in cervical cancer cell growth and metastasis.
Methods
Cell lines
HeLa and SiHa cervical cancer cell lines were obtained
from Shanghai Institute for Biological Sciences, Chinese
Academy of Sciences. The cervical adenocarcinoma cell
line HeLa containing HPV18 DNA, has a small telo-
centric chromosome in 98% of the cells and 100% aneu-
ploidy. The cervical squamous carcinoma cell line SiHa
containing HPV16 DNA, is a hypertriploid human cell
line with the modal chromosome number of 71, occur-
ring in 24% of cells. Cells were cultured in DMEM sup-
plemented with 10% fetal bovine serum and antibiotics
(Gibco BRL, Rockville, MD).
Isolation of HeLa and SiHa cell subclones
Cells at log phase were collected and adjusted to a dens-
ity of 10 cells/ml with RPMI-1640, then seeded into a
96-well plate (0.1 ml/well). The 96-well plate was
observed through a microscope, and then a marker was
made on the well containing a single cell. After being
cultured for 2–3 weeks at 37°C and 5% CO2 condition, a
good clone was selected and amplified. A total of 25 cell
subclones were obtained from HeLa cells and named
from HeLa-1 to HeLa-25, meanwhile a total of 23 sub-
clones were obtained from SiHa cells and named from
SiHa-1 to SiHa-23. The electrophoretic migration rates
of these subclones were measured by the cell electro-
phoretic instrument (DY-100, from College of Life Science,
Shandong University, China). A total of 15 cells /subclone
were measured and the averages were figured out. All data
were expressed as mean ± SE.
RNA interference
Self-inactivating lentivirus vector (GeneChem, Shanghai,
China) containing a CMV-driven GFP reporter and a U6promoter upstream of the cloning sites (Age I and
EcoR I) was used for cloning small hairpin RNAs
(shRNAs). The target sequence for SPARC was 50-
AACAA GACCTTCGACTCTTCC-30; the negative con-
trol sequence was 50-TTCTCCGAACGTGTCACGT-30.
HeLa-1 and SiHa-1 cells were cultured in six-well tissue
culture plates and infected with lentivirus at a multipli-
city of infection (MOI) of 60 for 24 h. Then the medium
was replaced with fresh complete medium. After 4 days,
cells were observed under fluorescence microscopy to
confirm that more than 80% of cells were GFP-positive.
Real-time quantitative RT-PCR (q-RT-PCR)
Total RNA was extracted using Trizol reagent (Invitro-
gen) and reversed transcribed. Quantitative real-time
PCR analysis was performed using ABI PRISM 7500
Real-Time PCR System (Applied Biosystems). Each well
(20 μl reaction volume) contained 10 μl Power SYBR
Green PCR master mix (Applied Biosystems), 1 μl of
each primer (5 μmol/l) and 1μl template. The primers
(Table 1) were designed by primer 5 software and
synthesized by TaKaRa Biotechnology (Dalian) Co., Ltd.
Western blot
Cells were lysed in RIPA buffer containing 1mM PMSF.
Fifty microgram of protein per lane was resolved by
SDS-PAGE, transferred to PVDF membrane and blocked
with 5% BSA. The membranes were first incubated with
primary antibody against SPARC (AF941, R&D Systems),
PCNA (bs-0754R, BIOSS), cyclin D1 (bs-0623R, BIOSS),
P53 (bs-0033R, BIOSS), P21 (bs-0741R, BIOSS), Bax
(bs-0127R, BIOSS) and Bcl-2 (bs-0032R, BIOSS) at
1:1000 dilutions overnight, and then incubated with sec-
ondary antibody horseradish peroxidase-conjugated anti-
goat or anti-rabbit IgG for 1 hour at room temperature.
Blots were developed using ECL method and band in-
tensity was analyzed using Gel-Pro Analyzer Software
(Media Cybernetics, Inc., Bethesda, MD).
Immunocytochemistry (ICC)
Logarithmic growth phase cells were seeded into 6-well
plate covered with coverslips inside, after 24 h culture,
coverslips were collected and subjected to Immunocyto-
chemistry (ICC). ICC was performed according to
streptavidin-biotin-peroxidase complex procedures. The
coverslips were incubated with anti-human SPARC anti-
body (AF941, R&D Systems) with working dilution
15μg/ml at 4°C overnight. The secondary antibody was
horseradish peroxidase conjugated anti-goat IgG. A
negative control was obtained by replacing the primary
antibody with normal rabbit immunoglobulin (IgG).
Positive expression of SPARC was defined as the pres-
ence of brown granules in the cytoplasm. The intensity
Table 1 Real time RT-PCR primers
Genes Forward and reverse primer Product length (bp)
SPARC F: 50-ACATAAGCCCAGTTCATCACCA-30 278
R: 50-ACAACCGATTCACCAACTCCA-30
E-cadherin F: 50-GGATTGCAAATTCCTGCCATTC-30 147
R: 50-AACGTTGTCCCGGGTGTCA-30
β-catenin F: 50-GCTGATCTTGGACTTGATATTGGTG -30 117
R: 50- GTCCATACCCAAGGCATCCTG -30
α-catenin F: 50- CTCTACTGCCACCAGCTGAACATC -30 154
R: 50- ATGCCTTCACTGTCTGCACCAC -30
Integrin β3 F: 50-TTCAATGCCACCTGCCTCAA-30 98
R: 50-TTGGCCTCAATGCTGAAGCTC-30
Integrin β1 F: 50-CAAGCAGGGCCAAATTGTGG-30 185
R: 50-CCTTTGCTACGGTTGGTTACATT-30
ILK F: 50- CCAATGTCCTGGTCGCATGTA -30 132
R: 50- CGTGTCACCAGTTCCCACAGA -30
FAK F: 50-CTGGCAGCATCTATCCAGGTCA-30 144
R: 50-TTGGCAACACTTGCCCAATC-30
P53 F: 50- AACGGTACTCCGCCACC-30 94
R: 50- CGTGTCACCGTCGTGGA-30
P21 F: 50- CACTCAGAGGAGGAAAATCCAGT −30 90
R: 50- TTCTGACATGGCGCCTGCCT −30
Cyclin D1 F: 50-CCGAGAAGCTGTGCATCTACAC-30 94
R: 50-AGGTTCCACTTGAGCTTGTTCAC-30
PCNA F: 50- CTGTAGCGGCGTTGT -30 133
R: 50- ACTTTCTCCTGGTTTGG -30
Bcl-2 F: 50- TCAGGGACGGGGTGAACT -30 143
R: 50- CAGGTGCCGGTTCAGGTACTC -30
Bax F: 50- CGCCGTGGACACAGACTC -30 108
R: 50- GCAAAGTAGAAAAGGGCGACAAC -30
u-PA F: 50-TCTGCCTGCCCTCGATGTATAAC-30 179
R: 50-GGTGGTGACTTCAGAGCCGTAGTAG-30
PAI-1 F: 50-GGTCTCCAAACCAGACGGTGA-30 188
R: 50-TGGCAATGTGACTGGAACAGAAATA-30
uPAR F: 50- ATCACCAGCCTTACCGAGGTTG -30 87
F: 50- ACGGCTTCGGGAATAGGTGAC -30
MMP2 F: 50-TGACATCAAGGGCATTCAGGAG-30 134
R: 50-TCTGAGCGATGCCATCAAATACA-30
MMP9 F: 50- CGCCCATTTCGACGATGAC -30 80
R: 50- CGCCATCTGCGTTTCCAA -30
TIMP1 F: 50- ACAGACGGCCTTCTGCAATTC-30 166
R: 50- GGTGTAGACGAACCGGATGTCA -30
TIMP2 F: 50- GTTCAAAGGGCCTGAGAAGGA -30 166
R: 50- CCAGGGCACGATGAAGTCA-30
GAPDH F: 5- GGGAAACTGTGGCGTGAT -30 299
R: 50- GAGTGGGTGTCGCTGTTGA -30
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used to evaluate SPARC expression.
Cell proliferation assays
Cell proliferation was determined by MTT assay and an-
chorage independent soft agar colony formation assay.
For MTT assay, 20μl MTT (5 mg/ml in PBS) was added
directly into each well of 96-well plate and incubated at
37°C for 4 h. Then media was removed and 200μl
DMSO was added to dissolve formazan crystals. The op-
tical density at 570 nm was read by a microplate reader
(Molecular Devices, Sunnyvale, CA).
For soft agar colony formation assay, 500 μl 2×DMEM
supplemented with 20% FBS was mixed with 500 μl 1.2%
Sea Plague agar and solidified in each well of a 24-well
plate to form base agar layer. For top agar layer, 25 μl
cells (5×103/ml) were mixed with 500 μl 2×DMEM and
500 μl 0.7% Sea Plague agar and added on top of base
agar layer. After grown for 14 days, colony formation
was monitored through a microscope. A cluster of ten
cells or more was defined as a colony.
Annexin V-PI assays for apoptosis
Cells were collected and washed twice with PBS, sus-
pended in 200 μl binding buffer and 10 μl Annexin
V-FITC for 20 minutes in the dark, and thereafter,
300 μl binding buffer and 5 μl propidium iodide (PI)
were added to each sample. The apoptotic cells were
determined by a flow cytometer (Becton Dickinson) with
CellQuest (Becton Dickinson) software.
Analysis of cell cycle distribution
Cells were harvested, washed with ice-cold PBS, and
stained with 50 μg/ml PI and 250 μg/ml RNase for 30
minutes. The percentage of cells in each phase of the
cell cycle was determined by a computer-programmed
ModFit LT2.0 DNA assay (Becton Dickinson) using a
flow cytometer.
Cell invasion assay and migration assay
Invasion assay was performed as described previously
[10]. Each Transwell (BD Biosciences, Bedford, MA) was
coated with 50 μl 1:3 dilution of Matrigel. Cells
(0.2 × 106) were resuspended in 200 μl serum-free media
and seeded into the upper chamber. Conditioned media
of NIH3T3 cell culture was filtered and added to the
lower chamber as a chemotactic factor. After 12 h, non-
invading cells remaining on the upper surface were
removed, and cells on the lower surface were fixed,
stained with hematoxylin and eosin (H&E), and counted.
Cell migration assay was also performed using Trans-
wells without Matrigel coating. Each experiment was
performed at least in triplicate. Invading cell numbers ofthree Boyden chambers were counted and the data were
expressed as mean ± SE.
Tumor xenografts in nude mice
BALB/C-nu/nu 5-week-old female nude mice were pur-
chased from National Resource Center for Rodent
Laboratory Animal of China. Four nude mice were
injected subcutaneously with 5.0×106 cells, and eight
nude mice were injected through the tail veins with the
same cells once a week for 3 consecutive weeks. The
mice were maintained in a sterile animal facility and
monitored for tumor growth. The volumes of tumors
were monitored at the indicated times and calculated
according to the formula: 0.5 × length ×width2. After 2
months, the mice injected subcutaneously were killed
and the tumors were dissected and measured to calcu-
late the volume. After 3 months, the nude mice injected
through the tail veins were killed and the lungs were dis-
sected. Paraffin sections of the lung tissues were made,
stained with hematoxylin and eosin (H&E) and observed
through a microscope. The average values were
expressed as mean ± SE. This animal experiment was
approved by the Institutional Animal Care and Use
Committee of Shandong University and was in compli-
ance with all regulatory guidelines.
Flow cytometry analysis
Cells at log phase were collected and adjusted to a dens-
ity of 1-5×106/ml with PBS, and then stained with 20μl
fluorescein isothiocyanate (FITC)-conjugated monoclo-
nal antibodies for 30 min at 25°C. Finally, the stained
cells were analyzed by a flow cytometer. Data analysis
was carried out using the program WinMDI. The test
was performed in quadruplicate.
Zymography
The zymography assay was performed in 10% SDS-
PAGE gel containing 0.1 mg/ml gelatin. 20μg protein
sample was loaded into each lane of SDS-PAGE gel.
After electrophoresis, the gel was washed twice with
2.5% Triton X-100 for 1h at room temperature to re-
move SDS and incubated at 37°C for overnight in the re-
action buffer. After staining with Coomassie brilliant
blue, MMPs expressions were identified as clear zones
against the blue background.
Statistical analysis
The results of cell and molecular biology data are
expressed as the mean ± SE. For comparison of means
between two groups, a two-tailed t-test was used, and
for comparison of means among three groups, one-way
ANOVA was used. Statistical analysis was performed
using SPSS software version 13.0. P-value < 0.05 was
considered statistically significant.
Chen et al. BMC Cancer 2012, 12:464 Page 5 of 15
http://www.biomedcentral.com/1471-2407/12/464Results
Establishment of high invasive subclones HeLa-1 and
SiHa-1 and low invasive subclones HeLa-25 and SiHa-23
By the limited dilution method, a total of 25 subclones
(HeLa-1-HeLa-25) and 23 subclones (SiHa-1-SiHa-23)
were obtained from HeLa and SiHa cells. According to
the electrophoretic migration rates, we selected HeLa-1
and SiHa-1 subclones that had the highest migration
rates (18.23±0.31 μm/s and 19.54±0.38 μm/s), and
HeLa-25 and SiHa-23 subclones that had the lowestFigure 1 Establishment of high invasive subclones and low invasive s
SiHa-1 and low invasive subclones HeLa-25 and SiHa-23 as examined by M
cell migration assay using Boyden chambers. (C) The images of cells invadi
using Boyden chambers. (Magnification ×200). *P<0.05 versus control.migration rates (9.87±0.14 μm/s and 8.73±0.15 μm/s).
HeLa-1 and SiHa-1 subclones showed higher prolifera-
tion and invasive activities than HeLa-25 and SiHa-23
subclones. The growth abilities in vitro of HeLa-1 and
SiHa-1 subclones were higher than HeLa-25 and
SiHa-23 subclones (Figure 1A). In the soft agar colony
formation assay, the colony number formed by HeLa-1
and SiHa-1 subclones (45.73±1.14 and 48.57±1.25) was
significantly higher than that formed by HeLa-25 and
SiHa-23 subclones (5.32±0.28 and 6.73±0.35, P<0.01). Inubclones. (A) The proliferations of high invasive subclones HeLa-1 and
TT assay. (B) The images of cells crossing PVPF filters as examined by
ng Matrigel-coated membranes as examined by cell invasion assay
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ing cell counts of HeLa-1 and SiHa-1 subclones were
much higher than that of HeLa-25 and SiHa-23 sub-
clones (218.48±4.75 and 265.24±5.36 vs. 76.64±3.41 and
85.91±3.87, P<0.01). In the Matrigel invasion assay
(Figure 1C), the average invading cell counts of HeLa-1
and SiHa-1 subclones were much higher than that of
HeLa-25 and SiHa-23 subclones (120.48±3.87 and
128.57±4.31 vs. 28.21±1.54 and 30.78±1.87, P < 0.01). In
the transplantation assay (Figure 2AB), the tumor-
forming rates of HeLa-1 and SiHa-1 subclones wereFigure 2 Tumor xenografts in nude mice. (A) Tumor growths of high in
25 and SiHa-23 observed continuously for 12 weeks. (B) Photograph of xen
H&E staining photos of xenografts dissected from nude mice after subcuta100% and that of HeLa-25 and SiHa-23 subclones were
only about 50%. The volumes of tumors formed by
HeLa-1 and SiHa-1 subclones were 14625.48±125.37 mm3
and 13167.25±128.68 mm3, much larger than that formed
by HeLa-25 and SiHa-23 subclones (343.54±21.86 mm3
and 487.35±28.75 mm3, P<0.01). The results of H&E
staining showed that the tumor xenografts formed by
the low invasive subclones HeLa-25 and SiHa-23 con-
sisted of more connective tissues and less tumor tis-
sues, compared to that formed by the high invasive
>subclones HeLa-1 and SiHa-1 (Figure 2C). HeLa-25vasive subclones HeLa-1 and SiHa-1 and low invasive subclones HeLa-
ografts dissected from nude mice after subcutaneous inoculation. (C)
neous inoculation. (Magnification ×200). *P<0.05 versus control.
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the lung metastasis rates of HeLa-1 and SiHa-1
groups were about 70%. In conclusion, HeLa-1 and
SiHa-1 subclones have the higher invasive potential in
contrast with HeLa-25 and SiHa-23 subclones.Figure 3 Expression of SPARC in high invasive subclones and low inv
subclones HeLa-1 and SiHa-1 and low invasive subclones HeLa-25 and SiHa
high invasive subclones HeLa-1 and SiHa-1 and low invasive subclones HeL
expressions of high invasive subclones HeLa-1 and SiHa-1 and low invasive
(Magnification ×200). *P<0.05 versus control.The expression of SPARC in high invasive subclones
HeLa-1 and SiHa-1 and low invasive subclones HeLa-25
and SiHa-23
We know that SPARC is associated with the progres-
sions of many human tumors. However, till now fewasive subclones. (A) SPARC protein expressions of high invasive
-23 as measured by Western blot. (B) SPARC mRNA expressions of
a-25 and SiHa-23 as measured by q-RT-PCR. (C) SPARC protein
subclones HeLa-25 and SiHa-23 as measured by ICC staining
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http://www.biomedcentral.com/1471-2407/12/464researches have been done about the functions of
SPARC in human cervical cancer cell growth and metas-
tasis. So we detect the different expressions of SPARC
between high invasive subclones HeLa-1 and SiHa-1 and
low invasive subclones HeLa-25 and SiHa-23. The
results of Western Blot (Figure 3A) showed that the
average band intensities of SPARC normalized toFigure 4 Verification of knockdown of SPARC expression by lentivirus
shRNA delivery efficiency. (Magnification × 200). (B) SPARC protein expressi
non-infected cells as measured by Western blot. (C) SPARC mRNA expressio
non-infected cells as measured by q-RT-PCR. (D) SPARC protein expressions
infected cells as measured by ICC staining (Magnification ×200). *P<0.05 veGAPDH in HeLa-1 and SiHa-1 groups were 0.97±0.15
and 1.38±0.14, much higher than that in HeLa-25 and
SiHa-23 groups (0.16±0.04 and 0.35±0.07, P<0.01).
Real-time RT-PCR and ICC (Figure 3BC) also revealed
that the expressions of SPARC were much higher in high
invasive subclones HeLa-1 and SiHa-1 than that in low
invasive subclones HeLa-25 and SiHa-23.-mediated RNA interference. (A) GFP expression images showed
ons of SPARC shRNA infected cells, control shRNA infected cells and
ns of SPARC shRNA infected cells, control shRNA infected cells and
of SPARC shRNA infected cells, control shRNA infected cells and non-
rsus control.
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RNA interference
To investigate the role of SPARC in cervical cancer, we
constructed lentivirus vector with SPARC shRNA and
infected high invasive subclones HeLa-1 and SiHa-1. After
viral infection, more than 80% cells were GFP-positive, in-
dicating a high efficiency of shRNA delivery (Figure 4A).
The results of Western Blot (Figure 4B) showed that the
average band intensities of SPARC normalized to GAPDH
in SPARC shRNA infected group, control shRNA infectedFigure 5 Effects of SPARC knockdown on cell growth, colony formatio
cells, control shRNA infected cells and non-infected cells as examined by M
infected cells, control shRNA infected cells and non-infected cells as measu
SPARC shRNA infected cells and control shRNA infected cells as measured
control shRNA infected cells and non-infected cells as measured by Annexgroup and non-infected group were separately 0.14±0.05,
0.90±0.17 and 0.92±0.13 for HeLa-1 subclone, and 0.07
±0.02, 0.76±0.09 and 0.80±0.07 for SiHa-1 subclone. As
shown in Figure 4C-D, Real-time RT-PCR and ICC also
confirmed the down-regulation of SPARC by its shRNA.
There was no significant difference between control
shRNA infected cells and non-infected cells. SPARC
expressions were decreased in high invasive subclones
HeLa-1 and SiHa-1 at both mRNA and protein levels after
RNA interference.n and apoptosis. (A) Cell proliferations of SPARC shRNA infected
TT assay. (B) Anchorage independent growth of SPARC shRNA
red by soft agar colony formation assay. (C) Cell-cycle distributions of
by flow cytometry. (D) Cell apoptosis of SPARC shRNA infected cells,
in V-PI assays. *P<0.05 versus control.
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http://www.biomedcentral.com/1471-2407/12/464Knockdown of SPARC expression suppressed cervical
cancer cell proliferation
We investigated the effects of SPARC knockdown on the
proliferations of both high invasive subclones HeLa-1 andFigure 6 Effects of SPARC knockdown on cell migration and invasion
migration assay using Boyden chambers. (B) The images of cells invading M
Boyden chambers. (Magnification ×200). (C) The average invading or migra
cells and non-infected cells. *P<0.05 versus control.SiHa-1. MTT results showed that SPARC knockdown sig-
nificantly reduced cell proliferations of HeLa-1 and
SiHa-1 (Figure 5A). In the soft agar colony formation
assay, HeLa-1 and SiHa-1 cells infected with SPARC. (A) The images of cells migrating PVPF filters as examined by cell
atrigel-coated membranes as examined by cell invasion assay using
ting cell counts of SPARC shRNA infected cells, control shRNA infected
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http://www.biomedcentral.com/1471-2407/12/464shRNA showed significant reduction in the colony forma-
tion (Figure 5B). No significant difference was found be-
tween control shRNA infected cells and non-infected
cells.
Knockdown of SPARC expression induced cell cycle arrest
at the G1/G0 phase
To understand the mechanism of SPARC in cervical
cancer cell proliferation, we used flow cytometry to
identify the specific phases of the cell cycle. As shown in
Figure 5C, HeLa-1 and SiHa-1 cells infected with SPARC
shRNA contained 20-30% more cells at the G1 or G0
(G1/G0) phase (P < 0.01), compared with the control
shRNA infected cells. These data indicated that knock-
down of SPARC expression inhibited the proliferation of
cervical cancer cells by blocking their progression from
the G1/G0 phase to the S phase during the cell cycle.
Knockdown of SPARC expression induced cervical cancer
cell apoptosis
As shown in Figure 5D, the percentage of apoptotic cells
infected with SPARC shRNA was much higher than that
in control shRNA group (P < 0.01). No significant differ-
ence was found between control shRNA infected cells and
non-infected cells. These data indicated that knockdown
of SPARC expression induced cervical cancer cell
apoptosis.
Knockdown of SPARC expression inhibited cervical cancer
cell migration and invasion
We further examined the effects of SPARC knockdown on
the migration and invasion abilities of HeLa-1 and SiHa-1
cells. As shown in Figure 6, knockdown of SPARC inhib-
ited cervical cancer cells invasion and migration. The simi-
lar data were achieved in HeLa-1 and SiHa-1 cells after
SPARC shRNA infections. The average invading or mi-
grating cell count of SPARC shRNA infected cells was
much less than that of control shRNA infected cells. No
significant difference was found between control shRNA
infected cells and non-infected cells.
Knockdown of SPARC expression inhibited tumor growth
and lung metastasis in nude mice
Tumor formation was performed in high invasive sub-
clone HeLa-1 cells infected by SPARC shRNA. Cells
were inoculated subcutaneously in nude mice and tumor
growth was measured after 2 months. As shown in
Figure 7AB, knockdown of SPARC showed a decrease in
the size of tumors, compared with its control counter-
part. The results of H&E staining showed that the tumor
xenografts formed by SPARC shRNA infected cells con-
sisted of more connective tissues and less tumor tissues
(Figure 7C). There was no significant difference between
control shRNA infected cells and non-infected cells inthe tumor formation of nude mice. Moreover, Figure 7D
shows the lung metastasis through a microscope after
tail vein injection into nude mice. About 50% lung me-
tastases were found after 3 months in the nude mice
injected with control shRNA infected cells, and the aver-
age lung colony size was 267.84±12.68 mm3, while no
lung metastasis was found after injection with SPARC
shRNA infected cells into nude mice.
Downstream molecules of SPARC in cervical cancer cell
To understand the mechanism of SPARC in cervical
cancer cell proliferation, apoptosis and invasion, the
downstream molecules of SPARC were detected by real-
time quantitative RT-PCR in high invasive subclone
HeLa-1 cells. As shown in Figure 8AB and Table 2, Cyc-
lin D1, PCNA, Bcl-2, MMP2 and MMP9 were signifi-
cantly down-regulated in SPARC shRNA infected cells,
the average band intensities of Cyclin D1, PCNA, and
Bcl-2 normalized to GAPDH in SPARC shRNA infected
group were separately 0.26±0.04, 0.36±0.03 and 0.21
±0.04, much lower than that in control shRNA infected
group (1.14±0.13, 1.26±0.15 and 0.96±0.10). Besides,
higher expression levels of E-cadherin, P53, P21 and Bax
were found in SPARC shRNA infected cells, the average
band intensities of P53, P21 and Bax normalized to
GAPDH in SPARC shRNA infected group were separ-
ately 0.89±0.11, 0.93±0.12 and 1.24±0.16, much higher
than that in control shRNA infected group (0.24±0.03,
0.16±0.02, and 0.38±0.08). There were no different
expressions of β-catenin, α-catenin, Integrin β3, Integrin
β1, ILK, FAK, u-PA, PAI-1, uPAR, TIMP1 and TIMP2
between SPARC shRNA infected cells and control
shRNA infected cells. Zymography results showed that
the MMPs expressions were significantly reduced in
SPARC shRNA infected cells (Figure 8C).
Discussion and conclusions
SPARC is a highly conserved, multifunctional matricellu-
lar protein that regulates matrix remodeling, cell adhe-
sion and migration, cell cycle regulation and
angiogenesis. Although there is growing evidence for an
important role for SPARC in a variety of cancers, there
is no unifying model, which explains all aspects of its
function [9,11]. For example, higher levels of SPARC ex-
pression have been reported in breast cancer [12,13],
melanoma [14,15], hepatocellular carcinoma [16,17],
prostate cancer [18] and colorectal cancer [19,20]. How-
ever, the opposite effect has also been demonstrated,
suggesting that SPARC may be able to inhibit tumori-
genesis or tumor progression in breast cancer [21,22],
ovarian carcinoma [23,24], hepatocellular carcinoma
[25], prostate cancer [26], and colorectal cancer [27,28].
In cervical cancer, recent researches reveal that
increased expression of SPARC is related to the
Figure 7 Effects of SPARC knockdown on tumor growth and lung metastasis in nude mice. (A) Photograph of xenografts dissected from
nude mice after subcutaneous inoculation (n=4). (B) Tumor growths of SPARC shRNA infected cells, control shRNA infected cells and non-
infected cells observed continuously for 8 weeks. (C) H&E staining photos of xenografts dissected from nude mice after subcutaneous inoculation.
(D) Photograph of lung metastasis through a microscope after inoculation through tail vein. (n=8) (Magnification ×200). *P<0.05 versus control.
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with aberrant methylation [29,30]. In our study, we
found that SPARC was highly expressed in the high in-
vasive subclones HeLa-1 and SiHa-1, compared to the
low invasive subclones HeLa-25 and SiHa-23. These
results revealed that SPARC was related to the invasive
phenotype of cervical cancer cells. Further researches
showed that lentivirus-mediated knockdown of SPARC
expression significantly suppressed cervical cancer cell
proliferation, induced cell apoptosis, and inhibited cell
invasion and metastasis.
In this study, using MTT assay, soft agar colony for-
mation assay and flow cytometer, we concluded thatknockdown of SPARC suppressed cervical cancer cell
proliferation. Flow cytometer showed that knockdown of
SPARC reduced the number of cells in S-phase, while
increased the number of cells in G1/G0-phase, indicat-
ing G1/G0 arrest. To understand the mechanism of
SPARC in cervical cancer cell proliferation, we detected
the different expressions of Cyclin D1, PCNA, P53 and
P21 between SPARC shRNA infected cells and control
shRNA infected cells. Cyclin D1, a member of G1
cyclins, and PCNA (proliferating cell nuclear antigen)
are proliferation biomarkers [31,32]. P53, a tumor sup-
pressor gene, and P21 (cyclin-dependent kinase inhibi-
tor), a key mediator of p53, can induce cell-cycle arrest
Figure 8 Downstream target genes of SPARC in cervical cancer cells. (A) E-cadherin, β-catenin, alpha-catenin, Integrin β3, Integrin β1, ILK,
FAK, P53, P21, Cyclin D1, PCNA, Bcl-2, Bax, u-PA, uPAR, PAI-1, MMP2, MMP9, TIMP1 and TIMP2 mRNA expressions as measured by q-RT-PCR. (B)
P53, P21, Cyclin D1, PCNA, Bcl-2 and Bax protein expressions in SPARC shRNA infected cells and control shRNA infected cells as measured by
Western blot. (C) MMPs expressions of SPARC shRNA infected cells, control shRNA infected cells and non-infected cells as measured by
zymography. *P<0.05 versus control.
Table 2 Flow cytometry analysis about E-cadherin,
integrin β1 and integrin β3
Percent positive cells P
SPARC shRNA Control shRNA
E-cadherin 80.38±5.73 24.85±2.64 <0.01
Integrin β1 95.35±6.67 97.43±8.12 >0.05
Integrin β3 53.78±3.37 55.67±3.62 >0.05
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http://www.biomedcentral.com/1471-2407/12/464in the G1-S checkpoint [33,34]. In this study, we found
that knockdown of SPARC expression could decrease
the expressions of Cyclin D1 and PCNA and increase
the expressions of P53 and P21, which suggested that
depletion of SPARC could inhibit cervical cancer cell
proliferation through activation of a p53⁄p21Cip1⁄Waf1
pathway dependent on G1-S checkpoint. In melanoma,
SPARC also could regulate cell cycle progression and
proliferation through the p53/p21 (Cip1/Waf1) pathway
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http://www.biomedcentral.com/1471-2407/12/464[35]. In brief, SPARC could play an important role in
cervical cancer cell proliferation by controlling cell cycle
progression, but how depletion of SPARC can lead to ac-
tivation of the p53/p21 (Cip1/Waf1) signaling pathway
needs further study.
Further researches showed that knockdown of SPARC
induced cervical cancer cell apoptosis. Apoptosis is
modulated partially by Bcl-2 family including apoptosis-
inhibiting genes (Bcl-2, Bcl-xL, Mcl-1, A1 and Bcl-w)
and apoptosis-accelerating genes (Bax, Bak, Bcl-xS and
Bim) [36]. In this study, we found that knockdown of
SPARC could decrease the expression of apoptosis-
inhibiting gene Bcl-2 and increase the expression of
apoptosis-accelerating gene Bax, indicating the down-
regulated ratio of Bcl-2/Bax. Our result revealed that
SPARC could play an effect on apoptosis by changing
the ratio of Bcl-2/Bax. Similar results were found in
human melanoma; suppression of SPARC in several
human melanoma cells triggered apoptotic cell death
dependent on p53 and induction of Bax [37]. Apoptosis,
programmed cell death, is vital for normal development
and tissue homeostasis. Our data suggested that SPARC
as an antistress factor could promote cervical cancer cell
survival through suppression of apoptotic pathways.
Using Boyden chambers and xenografts in nude mice, we
concluded that knockdown of SPARC expression inhibited
cervical cancer cell invasion and metastasis. To clarify the
mechanism of SPARC in cervical cancer cell invasion and
metastasis, after viral infection, we detected the expression
of the cellular adhesion molecule E-cadherin and integrins,
which mediated cell-cell adhesion and cell-extracellular
matrix adhesion, and the expression of proteolytic enzymes
such as plasminogen activator/plasmin system (uPA-uPAR)
and matrix metalloproteinases (MMPs), which degraded
the extracellular matrix (ECM). These results revealed that
knockdown of SPARC up-regulated the expression of E-
cadherin and had no effect on the expressions of integrin
β1 and integrin β3. SPARC can break down cell-cell con-
nections to improve tumor invasion by changing E-
cadherin expression. Similar results were also found in mel-
anoma [38,39]; SPARC can down-regulate E-cadherin and
stimulate an invasive melanoma phenotype. Next, knock-
down of SPARC decreased the expressions of MMP2 and
MMP9, but no significant differences were found in the
expressions of u-PA, uPAR, PAI-1, TIMP1 and TIMP2
between SPARC shRNA infected cells and control
shRNA infected cells. SPARC can make the extracellular
matrix degradation by MMP2 and MMP9. Similar
results were also found in glioma [40,41]. Our data sug-
gested that depletion of SPARC could promote the
homophilic cell-cell adhesion by up-regulating E-cad-
herin and restrained extracellular matrix degradation by
down-regulating MMPs expressions to inhibit cervical
cancer cell invasion and metastasis.In conclusion, SPARC is associated with cervical cancer
cell growth and metastasis. Knockdown of SPARC expres-
sion significantly suppresses cervical cancer cell prolifera-
tion, induces cell apoptosis and inhibits cell invasion and
metastasis. All of these informations contribute to a better
understanding that SPARC, as a promoter, improves cer-
vical cancer cell proliferation, invasion and metastasis.
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